NEW YORK, March 18, 2023 /PRNewswire/ — Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the remedy of palmar hyperhidrosis making use of its patented microchannel technologies™. DTX-024 is a hugely purified and clinically tested injectable neuromodulator derived from neurotoxins made by Clostridium botulinum.
Aquavit Logo (PRNewsfoto/Aquavit Pharmaceuticals, Inc.)
Alongside Aquavit’s biosimilar system for its botulinum toxin, this will be the very first in the planet, indicated for palmar hyperhidrosis, authorized by FDA.
Aquavit has been investing in proprietary delivery technologies and connected intellectual home for botulinum toxin. This is a strategic move that puts them ahead of the curve in the speedy-developing multi-billion-dollar botulinum toxin marketplace.
To correctly execute the tactic, Aquavit has not too long ago bolstered its executive group with seasoned veterans from the market and the academia.
Dr. David Crean, PhD, MBA has been named Chief Monetary Officer of Aquavit Holdings. He has get- and sell-side experience in mergers & acquisitions (M&A), partnering and investments inside the life sciences and healthcare sectors functioning inside strategic biopharmaceutical providers, private equity, investment banking and venture capital. He commenced his profession inside biopharmaceutical providers far more than 30 years ago, most notably at Allergan, an Abbvie Corporation, exactly where he lead deal execution for each technologies, item, and corporation acquisitions and divestitures across a broad variety of therapeutic regions and enterprise units which includes injectable and topical health-related aesthetics, dermatology, neurology, and ophthalmology. He serves on quite a few boards which includes each public and private providers and has been awarded quite a few recognitions which includes San Diego’s 500 Most Influential persons for the previous 4 years (2019 -2022), 2020 Top rated Believed Leaders by Axial, M&A Advisor of the Year in 2019, and the 2018 Healthcare Hero Award.
Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Investment Banking Representative of BA Securities LLC, Member FINRA SIPC.
Dr. Churlsu Kwon, MD. PhD. MPH., has been named Chief Healthcare Officer. He is a educated neurosurgeon and neuroscientist who brings a wealth of encounter and information to scientific developments, drug improvement and approval, and new drug discovery. He holds his degrees from University of Oxford and Harvard Healthcare College and at present holds an academic position at Columbia Healthcare College.
With Aquavit’s verified track record of building and launching international brands, such as AQUAGOLD®, the corporation has demonstrated their potential to effectively bring revolutionary goods to marketplace. With their deep information of botulinum toxin and substantial network of physicians, Aquavit is nicely-positioned to make a important influence in the market.
“The neurotoxin marketplace is expanding swiftly, with growing demand for revolutionary goods and customized remedy plans. There is at present no FDA approval for palmar hyperhidrosis and by means of our novel route of administration we will be in a position to supply new options to meet the evolving demands of individuals in pathologies that are really debilitating. The provision of access for this population is a step in the correct path towards enhancing their overall health and nicely-becoming. ” Churl-Su Kwon, CMO Aquavit.
Aquavit is an revolutionary healthcare corporation that gives a complete variety of proprietary pharmaceutical, biotech and health-related device technologies. Aquavit focuses on customized medicine to enhance patients’ overall health, maximize the efficiency of our health-related neighborhood, and assistance the pharmacoeconomics of payers.
View original content material to download multimedia:https://www.prnewswire.com/news-releases/aquavit-files-more-ind-for-dtx-024-a-new-botulinum-toxin-with-microchannel-technologies-for-palmar-hyperhidrosis-301775589.html
Supply Aquavit Holdings
One thought on “Aquavit Files Extra IND for DTX-024, a New Botulinum Toxin With Microchannel Technology™ for Palmar Hyperhidrosis”